Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
Successful treatment of solid tumors relies on the ability of drugs to penetrate into the tumor tissue.
We examined the correlation of panitumumab (an anti-epidermal growth factor [EGFR] antibody) tumor penetration and EGFR saturation, a potential obstacle in large molecule drug delivery, using pharmacokinetics, pharmacodynamics, and tumor growth rate in an A431 epidermoid carcinoma xenograft model of human cancer. To determine receptor saturation, receptor occupancy, and levels of proliferation markers, immunohistochemical and flow cytometric methods were used. Pharmacokinetic data and modeling were used to calculate growth characteristics of panitumumab-treated tumors.
Treatment with panitumumab in vivo inhibited pEGFR, Ki67 and pMAPK levels vs control. Tumor penetration and receptor saturation were dose- and time-dependent, reaching 100% and 78%, respectively. Significant tumor inhibition and eradication (p < 0.05) were observed; plasma concentration associated with tumor eradication was estimated to be 0.2 μg/ml. The tumor inhibition model was able to describe the mean tumor growth and death rates.
These data demonstrate that the antitumor activity of panitumumab correlates with its ability to penetrate into tumor tissue, occupy and inhibit activation of EGFR, and inhibit markers of proliferation and MAPK signaling.
- Tunggal, JK, Cowan, DS, Shaikh, H, Tannock, IF (1999) Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Canc Res 5: pp. 1583-1586
- Adams, GP, Schier, R, McCall, AM, Simmons, HH, Horak, EM, Alpaugh, RK, Marks, JD, Weiner, LM (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: pp. 4750-4755
- Beckman, RA, Weiner, LM, Davis, HM (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109: pp. 170-179 CrossRef
- Baker, SD, Hu, S (2009) Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther 85: pp. 208-211 CrossRef
- Siegel-Lakhai, WS, Beijnen, JH, Schellens, JH (2005) Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10: pp. 579-589 CrossRef
- Gullick, WJ (1991) Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: pp. 87-98
- Nicholson, RI, Gee, JM, Harper, ME (2001) EGFR and cancer prognosis. Eur J Cancer 37: pp. S9-S15 CrossRef
- Herbst, RS, Shin, DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: pp. 1593-1611 CrossRef
- Ritter, CA, Arteaga, CL (2003) The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30: pp. 3-11 CrossRef
- Yarden, Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37: pp. S3-S8 CrossRef
- Modjtahedi, H, Eccles, S, Sandle, J, Box, G, Titley, J, Dean, C (1994) Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 54: pp. 1695-1701
- Salomon, DS, Normanno, N, Ciardiello, F, Brandt, R, Shoyab, M, Todaro, GJ (1995) The role of amphiregulin in breast cancer. Breast Canc Res Treat 33: pp. 103-114 CrossRef
- Foon, KA, Yang, XD, Weiner, LM, Belldegrun, AS, Figlin, RA, Crawford, J, Rowinsky, EK, Dutcher, JP, Vogelzang, NJ, Gollub, J (2004) Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58: pp. 984-990 CrossRef
- Jakobovits, A, Amado, RG, Yang, X, Roskos, L, Schwab, G (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25: pp. 1134-1143 CrossRef
- Yang, XD, Jia, XC, Corvalan, JR, Wang, P, Davis, CG (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38: pp. 17-23 CrossRef
- Yang, XD, Jia, XC, Corvalan, JR, Wang, P, Davis, CG, Jakobovits, A (1999) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: pp. 1236-1243
- Pal, SK, Pegram, M (2005) Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anti Canc Drugs 16: pp. 483-494 CrossRef
- Douillard, JY, Siena, S, Cassidy, J, Tabernero, J, Burkes, R, Barugel, M, Humblet, Y, Bodoky, G, Cunningham, D, Jassem, J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: pp. 4697-4705 CrossRef
- Peeters, M, Price, TJ, Cervantes, A, Sobrero, AF, Ducreux, M, Hotko, Y, Andre, T, Chan, E, Lordick, F, Punt, CJ (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: pp. 4706-4713 CrossRef
- Van Cutsem, E, Peeters, M, Siena, S, Humblet, Y, Hendlisz, A, Neyns, B, Canon, JL, Van Laethem, JL, Maurel, J, Richardson, G (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: pp. 1658-1664 CrossRef
- Weiner, LM, Belldegrun, AS, Crawford, J, Tolcher, AW, Lockbaum, P, Arends, RH, Navale, L, Amado, RG, Schwab, G, Figlin, RA (2008) Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14: pp. 502-508 CrossRef
- Freeman, DJ, Juan, T, Reiner, M, Hecht, JR, Meropol, NJ, Berlin, J, Mitchell, E, Sarosi, I, Radinsky, R, Amado, RG (2008) Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7: pp. 184-190 CrossRef
- Lofgren, JA, Dhandapani, S, Pennucci, JJ, Abbott, CM, Mytych, DT, Kaliyaperumal, A, Swanson, SJ, Mullenix, MC (2007) Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 178: pp. 7467-7472
- Simeoni, M, Magni, P, Cammia, C, De Nicolao, G, Croci, V, Pesenti, E, Germani, M, Poggesi, I, Rocchetti, M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64: pp. 1094-1101 CrossRef
- Sigismund, S, Argenzio, E, Tosoni, D, Cavallaro, E, Polo, S, Di Fiore, PP (2008) Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 15: pp. 209-219 CrossRef
- Friedman, LM, Rinon, A, Schechter, B, Lyass, L, Lavi, S, Bacus, SS, Sela, M, Yarden, Y (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 102: pp. 1915-1920 CrossRef
- Flessner, MF, Choi, J, Credit, K, Deverkadra, R, Henderson, K (2005) Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin Cancer Res 11: pp. 3117-3125 CrossRef
- Foltz, I, King, CT, Liang, M (2005) Panitumumab Induces Internalization of the Epidermal Growth Factor Receptor (EGFr) [abstract B43]. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics (Proceedings).
- Hidalgo, M, Siu, LL, Nemunaitis, J, Rizzo, J, Hammond, LA, Takimoto, C, Eckhardt, SG, Tolcher, A, Britten, CD, Denis, L (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: pp. 3267-3279
- Smith, NF, Baker, SD, Gonzalez, FJ, Harris, JW, Figg, WD, Sparreboom, A (2008) Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br J Cancer 98: pp. 1630-1632 CrossRef
- Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- July 2012
- Online ISSN
- BioMed Central
- Additional Links
- Monoclonal antibody
- Industry Sectors
- Author Affiliations
- 1. Amgen Inc, Thousand Oaks, CA, USA
- 2. Charles River Laboratories, Pathology Associates, Frederick, MD, USA